Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
On Tuesday, Blue Orca Capital released a report on Insulet Corporation (NASDAQ:PODD), saying it is short on the insulin delivery patch pump manufacturer.
週二，Blue Orca Capital發佈了Insulet Corporation（納斯達克股票代碼：PODD）的一份報告，稱該公司缺少胰島素輸送貼片泵製造商。
The report added that Blue Orca is long on its upstart Korean competitor EOFlow Co Ltd as last week the Court of Appeals for the Federal Circuit killed a preliminary injunction that protected Insulet's key monopoly against competition from EOFlow.
該報告補充說，Blue Orca長期以來一直是其崛起的韓國競爭對手EoFlow Co Ltd。上週，聯邦巡迴上訴法院取消了一項保護Insulet的關鍵壟斷地位免受EoFlow競爭的初步禁令。
The report adds that the injunction is undisclosed to investors.
該報告補充說，該禁令未向投資者披露。
The report notes, "In our opinion, it is highly misleading for Insulet to conceal from investors that the appellate court killed the very injunction which protected its competitive moat and was so material to its stock that, when the injunction was granted, its market capitalization gained $1.8 billion. This injunction is now dead. Competition is here."
該報告指出：“我們認爲，Insulet向投資者隱瞞上訴法院取消了保護其競爭護城河且對其股票如此重要的禁令，以至於禁令頒佈時，其市值增加了18億美元，這極具誤導性。該禁令現已失效。競爭就在這裏。”
Insulet has maintained a stronghold on tubeless insulin patch pumps, constituting a significant portion of its revenue.
Insulet一直保持着無內胎胰島素貼片泵的據點，佔其收入的很大一部分。
However, EOFlow's introduction of the "EOPatch" posed a substantial threat to this monopoly, prompting legal action from Insulet.
但是，EoFlow推出的 “EoPatch” 對這種壟斷構成了重大威脅，促使Insulet採取了法律行動。
Surprisingly, the U.S. district court initially granted Insulet a preliminary injunction against EOFlow thwarting Medtronic Plc's (NYSE:MDT) acquisition plans.
令人驚訝的是，美國地方法院最初向Insulet下達了針對EoFlow的初步禁令，該禁令阻礙了美敦力集團（紐約證券交易所代碼：MDT）的收購計劃。
This decision bolstered Insulet's market position, leading to a surge in its market capitalization.
這一決定鞏固了Insulet的市場地位，導致其市值激增。
Medtronic announced it would acquire EOFlow in May 2023 for $738 million, but in December, the medtech giant terminated the deal.
美敦力宣佈將在2023年5月以7.38億美元的價格收購EoFlow，但在12月，這家醫療科技巨頭終止了這筆交易。
With the EOFlow deal, Medtronic could add EOPatch to its existing AID system and quickly offer tubeless automated insulin delivery systems in the U.S. to directly compete with Insulet's flagship product, the OmniPod 5.
通過EoFlow協議，美敦力可以在其現有的AID系統中增加eoPatch，並迅速在美國提供無管自動胰島素輸送系統，直接與Insulet的旗艦產品OmniPod 5競爭。
EOFlow appealed the decision, and after oral arguments, the appellate court delivered a verdict in favor of EOFlow, nullifying the preliminary injunction.
EoFlow對該決定提出上訴，經過口頭辯論，上訴法院作出了有利於EoFlow的判決，宣佈初步禁令無效。
The court's order undermines Insulet's protective barrier and opens avenues for competition in the automated insulin delivery systems market.
法院的命令破壞了Insulet的保護屏障，爲自動胰島素輸送系統市場的競爭開闢了途徑。
The impending drop in Insulet's share price is anticipated to exceed 15% as investors digest the implications of the court ruling.
隨着投資者消化法院裁決的影響，預計Insulet股價即將下跌的幅度將超過15％。
Conversely, EOFlow stands to benefit from a resurgence in its stock value, potentially reclaiming a 600% gain from its pre-injunction levels.
相反，EoFlow將受益於其股票價值的回升，有可能從禁令前的水平上收回600％的漲幅。
The flawed legal reasoning behind the initial injunction underscores the precariousness of Insulet's position in the face of emerging competition. The appellate court's decision marks a pivotal moment for both companies, with significant ramifications for the AID systems industry.
最初的禁令背後的法律理由有缺陷，凸顯了Insulet在面對新興競爭中的地位的不穩定性。上訴法院的裁決標誌着兩家公司的關鍵時刻，對援助系統行業產生了重大影響。
Last week, Insulet reported first quarter adjusted EPS of $0.73, beating the consensus of $0.39.
上週，Insulet公佈的第一季度調整後每股收益爲0.73美元，超過了市場預期的0.39美元。
The company reported sales of $441.7 million, beating the consensus of $424.05 million, including Omnipod revenue of $433 million, an increase of 21.1%.
該公司公佈的銷售額爲4.417億美元，超過了預期的4.2405億美元，其中包括4.33億美元的Omnipod收入，增長21.1％。
Price Action: PODD shares are up 5.11% at $169.26 at last check Tuesday.
價格走勢：週二最後一次檢查時，PODD股價上漲5.11％，至169.26美元。
Photo via Company
照片來自公司
譯文內容由第三人軟體翻譯。